Houston, Texas 77030

  • Hematologic Malignancies


To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Study summary:

Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.


Histologic proof of one of: - AML, ALL, or AUL - MDS or CMML - CML - OR undergoing bone marrow transplantation. Participants should be: - off therapy for at least two weeks - At least 18 years old or older - Using adequate contraception if of child-bearing capability.



Primary Contact:

Study Chair
Michael Andreeff, MD, PhD
M.D. Anderson Cancer Center

Backup Contact:


Location Contact:

Houston, Texas 77030
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.